FDA Approves First Treatment for Fatty Liver Scarring Disease

Nonalcoholic Fatty Liver Disease may be represented by an increase in one bacteria, in a similar way the microbiome is a biomarker for obesity and end-stage liver fibrosis.

Patients suffering from scarring due to fatty liver disease now have a new treatment option: Rezdiffra, a medication recently approved by the U.S. Food and Drug Administration.

The main ingredient in Rezdiffra is resmetirom, and it is intended to be used in conjunction with diet and exercise to treat non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring. This approval brings a much-needed standard of care treatment for a condition that affects up to 15 million adults in the U.S., according to the American Liver Foundation.